Bioenvision (BIVN) is currently developing products for hematologic malignancies, solid tumors and autoimmune diseases.
Bioenvision is planning to develop products for other therapeutic areas as well. In addition, the Company has in-licensed technologies to reduce the impact of blood-borne and hospital-acquired infections.
Bioenvision's product line can be viewed here.
BIVN Investor Highlights
Bioenvision has teamed up with Genzyme Corp. to develop clofarabine, a treatment for leukemia in children, the magazine said. Bioenvision aims to expand its use for elderly patients with acute myeloid leukemia in Europe, where it has marketing rights. Steven Rouhandeh, chief executive of SCO, is quoted by BusinessWeek as saying that when Europe approves clofarabine for adults, "Bioenvision will rocket," adding that by then, Genzyme might opt to buy Bioenvision. A decision is expected in 2007. Soros Fund Management and Perseus-Soros BioPharma Fund own a combined 12 percent stake in BIVN according to BusinessWeek.
Bioenvision's (BIVN) primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra, Modrenal (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing Suvus which is currently in clinical development for refractory chronic hepatitis C infection.
The company also offers various anti-infective technologies, including the OLIGON technology, an advanced biomaterial that has been incorporated into various FDA approved medical devices. In addition, it provides an animal health product, Vetoryl, for the treatment of Cushing's disease in dogs; and Velostan, a cytostatic drug under investigation as an anticancer agent and as an antimicrobial. The company sells its products to wholesale distributors and directly to hospitals, clinics, and retail pharmacies in the United States and the United Kingdom. It has co-development partnership with Genzyme Corporation.
Disclosure: Author has no position in BIVN
BIVN 1-yr chart